VectivBio Holding AG (NAS:VECT) Other Financing

: $-4.69 Mil (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

VectivBio Holding AG's Other Financing for the six months ended in Jun. 2022 was $-4.60 Mil.

VectivBio Holding AG's Other Financing for the trailing twelve months (TTM) ended in Jun. 2022 was $-4.69 Mil.

VectivBio Holding AG Other Financing Historical Data

The historical data trend for VectivBio Holding AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VectivBio Holding AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Other Financing

0.48

-1.33

-12.66

VectivBio Holding AG Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Other Financing		-	-	-12.57	-0.10	-4.60

VectivBio Holding AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-4.69 Mil.

VectivBio Holding AG Other Financing Related Terms

Thank you for viewing the detailed overview of VectivBio Holding AG's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

VectivBio Holding AG (NAS:VECT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VectivBio Holding AG (NAS:VECT) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

Aeschenvorstadt 36, Basel, CHE, 4051

Website

https://www.vectivbio.com

VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.